Patents Assigned to ANGIEX, INC.
  • Antibody-oligonucleotide conjugates
    Patent number: 12458705
    Abstract: Conjugates are provided, comprising a targeting protein, e.g., an anti-TM4SFI antibody or antigen or binding fragments thereof. Methods of manufacture and use of said conjugates are also described.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: November 4, 2025
    Assignee: ANGIEX, INC.
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward Ha
  • Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
    Patent number: 12428477
    Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Methods of use of said ADCs are also described.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: September 30, 2025
    Assignee: ANGIEX, INC.
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Edward H. Ha, Leonard G. Presta, Manish S. Hudlikar
  • Anti-TM4SF1 antibodies and methods of using same
    Patent number: 11208495
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: December 28, 2021
    Assignee: ANGIEX, INC.
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta